Therapeutic Developments in AML Lead to Sequencing Questions
Published: Wednesday, Jul 03, 2019
Robert L. Redner, MD
The FDA approval of 8 new agents in the acute myeloid leukemia (AML) paradigm in the past 3 years has offered more options for targeted treatment, leading to further trials on combination and sequencing strategies, explained Robert L. Redner, MD.
... to read the full story